IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Recent Pullback [Yahoo! Finance]
Ionis Pharmaceuticals (IONS) had its price target lowered by TD Cowen from $110.00 to $108.00. They now have a "buy" rating on the stock.
Ionis Pharmaceuticals (IONS) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".
Ionis (IONS) Q4 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Joseph
Form DEF 14A IONIS PHARMACEUTICALS For: Jun 04
Form ARS IONIS PHARMACEUTICALS For: Dec 31
Form DEFA14A IONIS PHARMACEUTICALS
Form 8-K IONIS PHARMACEUTICALS For: Apr 21
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.